Erlotinib
- Generic Name
- Erlotinib
- Brand Names
- Tarceva
- Drug Type
- Small Molecule
- Chemical Formula
- C22H23N3O4
- CAS Number
- 183321-74-6
- Unique Ingredient Identifier
- J4T82NDH7E
- Background
Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloproliferative disorders.
- Indication
Erlotinib is indicated for:
The safety and efficacy of erlotinib have not been established for patients with NSCLC whose tumors show other EGFR mutations. Additionally it is not recommended for use in combination with platinum-based chemotherapy.
- Associated Conditions
- Locally Advanced Pancreatic Cancer (LAPC), Metastatic Non-Small Cell Lung Cancer, Pancreatic Metastatic Cancer, Unresectable Pancreatic Cancer
- Associated Therapies
- -
A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2010-05-04
- Last Posted Date
- 2019-02-05
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 29
- Registration Number
- NCT01115803
- Locations
- 🇫🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Villejuif, France
Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)
- Conditions
- Interventions
- First Posted Date
- 2010-04-27
- Last Posted Date
- 2021-08-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 21
- Registration Number
- NCT01110876
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Phase 2 Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma
- First Posted Date
- 2010-04-22
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- George Albert Fisher
- Target Recruit Count
- 1
- Registration Number
- NCT01108458
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Study of Erlotinib With or Without Investigational Drug (CS-7017) in Subjects With Advanced Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-04-09
- Last Posted Date
- 2020-06-16
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 90
- Registration Number
- NCT01101334
- Locations
- 🇰🇷
Severance Hospital, Seoul, Korea, Republic of
🇰🇷Hwasun Hospital, Jeonnam, Korea, Republic of
🇮🇳Apollo Speciality Hospital, Chennai, Tamil Nadu, India
Erlotinib Combined With Radiotherapy in Patients With Non-resectable Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2010-03-24
- Last Posted Date
- 2010-05-17
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 75
- Registration Number
- NCT01091376
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Erlotinib in Higher Risk Myelodysplastic Syndrome
- First Posted Date
- 2010-03-12
- Last Posted Date
- 2016-11-08
- Lead Sponsor
- Groupe Francophone des Myelodysplasies
- Target Recruit Count
- 30
- Registration Number
- NCT01085838
- Locations
- 🇫🇷
CHU d'Angers, Angers, France
🇫🇷CHRU Huriez, Lille, France
🇫🇷Hôpital Avicenne, Bobigny, France
Phase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell Cancers (SCC) of the Skin
- First Posted Date
- 2010-01-29
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 10
- Registration Number
- NCT01059305
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera
- First Posted Date
- 2009-12-24
- Last Posted Date
- 2020-08-24
- Lead Sponsor
- University of Oklahoma
- Target Recruit Count
- 5
- Registration Number
- NCT01038856
- Locations
- 🇺🇸
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
- Conditions
- Interventions
- First Posted Date
- 2009-12-15
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- OSI Pharmaceuticals
- Target Recruit Count
- 25
- Registration Number
- NCT01032070
- Locations
- 🇺🇸
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
🇺🇸Dana-Farber Cancer Institute Department of Pediatric Neuro-oncology, Boston, Massachusetts, United States
🇺🇸University of Miami, Miami, Florida, United States
Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
- First Posted Date
- 2009-12-08
- Last Posted Date
- 2016-01-29
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 202
- Registration Number
- NCT01027598
- Locations
- 🇺🇸
Oncology Hematology Care, Cincinnati, Ohio, United States
🇺🇸South Carolina Oncology Associates, PA, Columbia, South Carolina, United States
🇺🇸Tennessee Oncology, PLLC, Nashville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.